Strong Revenue Growth
Bavarian Nordic reported a 33% improvement in revenues for the first half of 2025 compared to the previous year, resulting in an EBITDA margin of 32%.
Successful Vaccine Sales
The company sold 5 million doses of vaccines, saving 5 million lives in the first half of the year.
Travel Health Segment Growth
Travel Health saw a 24% improvement, driven by strong sales of rabies and TBE vaccines. The rabies vaccine saw a 26% growth in Q2 and 37% for the first half of the year.
Chikungunya Vaccine Launch
The Chikungunya vaccine is now approved in the EU, U.S., and U.K., with launches in Germany and France. The company expects this vaccine to be a key asset in the Travel Health portfolio.
Public Preparedness Contracts
Bavarian Nordic secured DKK 3.1 billion in Public Preparedness contracts, exceeding the base business expectations.
Priority Review Voucher Sale
The sale of a Priority Review Voucher resulted in net income of DKK 810 million, potentially improving the EBITDA margin to 42% by year-end.